nodes	percent_of_prediction	percent_of_DWPC	metapath
Droxidopa—ADRA2C—attention deficit hyperactivity disorder	0.544	0.701	CbGaD
Droxidopa—ADRA2A—attention deficit hyperactivity disorder	0.232	0.299	CbGaD
Droxidopa—SLC6A2—locus ceruleus—attention deficit hyperactivity disorder	0.00792	0.174	CbGeAlD
Droxidopa—SLC6A2—autonomic nervous system—attention deficit hyperactivity disorder	0.00421	0.0923	CbGeAlD
Droxidopa—DDC—forebrain—attention deficit hyperactivity disorder	0.00206	0.0451	CbGeAlD
Droxidopa—PAH—nervous system—attention deficit hyperactivity disorder	0.00196	0.043	CbGeAlD
Droxidopa—PAH—central nervous system—attention deficit hyperactivity disorder	0.00189	0.0414	CbGeAlD
Droxidopa—ADRA1D—forebrain—attention deficit hyperactivity disorder	0.00159	0.0348	CbGeAlD
Droxidopa—PAH—brain—attention deficit hyperactivity disorder	0.0015	0.0329	CbGeAlD
Droxidopa—DDC—midbrain—attention deficit hyperactivity disorder	0.00136	0.0298	CbGeAlD
Droxidopa—ADRB1—forebrain—attention deficit hyperactivity disorder	0.00115	0.0253	CbGeAlD
Droxidopa—DDC—nervous system—attention deficit hyperactivity disorder	0.00112	0.0245	CbGeAlD
Droxidopa—DDC—central nervous system—attention deficit hyperactivity disorder	0.00108	0.0236	CbGeAlD
Droxidopa—SLC6A2—forebrain—attention deficit hyperactivity disorder	0.000981	0.0215	CbGeAlD
Droxidopa—ADRB1—cardiovascular system—attention deficit hyperactivity disorder	0.000975	0.0214	CbGeAlD
Droxidopa—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.000912	0.02	CbGeAlD
Droxidopa—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.000881	0.0193	CbGeAlD
Droxidopa—Levonordefrin—ADRA2C—attention deficit hyperactivity disorder	0.00087	0.114	CrCbGaD
Droxidopa—ADRA1D—nervous system—attention deficit hyperactivity disorder	0.000862	0.0189	CbGeAlD
Droxidopa—DDC—brain—attention deficit hyperactivity disorder	0.000855	0.0187	CbGeAlD
Droxidopa—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.000849	0.0186	CbGeAlD
Droxidopa—ADRA1D—central nervous system—attention deficit hyperactivity disorder	0.00083	0.0182	CbGeAlD
Droxidopa—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000771	0.0169	CbGeAlD
Droxidopa—SLC16A10—cerebellum—attention deficit hyperactivity disorder	0.000722	0.0158	CbGeAlD
Droxidopa—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000694	0.0152	CbGeAlD
Droxidopa—ADRA1B—brain—attention deficit hyperactivity disorder	0.000674	0.0148	CbGeAlD
Droxidopa—ADRA1D—brain—attention deficit hyperactivity disorder	0.000659	0.0144	CbGeAlD
Droxidopa—Methyldopa—COMT—attention deficit hyperactivity disorder	0.000657	0.0859	CrCbGaD
Droxidopa—ADRB1—nervous system—attention deficit hyperactivity disorder	0.000626	0.0137	CbGeAlD
Droxidopa—ADRB1—central nervous system—attention deficit hyperactivity disorder	0.000603	0.0132	CbGeAlD
Droxidopa—ADRA2C—midbrain—attention deficit hyperactivity disorder	0.000574	0.0126	CbGeAlD
Droxidopa—L-DOPA—DRD5—attention deficit hyperactivity disorder	0.000547	0.0714	CrCbGaD
Droxidopa—SLC6A2—nervous system—attention deficit hyperactivity disorder	0.000533	0.0117	CbGeAlD
Droxidopa—Norepinephrine—ADRA2C—attention deficit hyperactivity disorder	0.000516	0.0674	CrCbGaD
Droxidopa—SLC6A2—central nervous system—attention deficit hyperactivity disorder	0.000513	0.0112	CbGeAlD
Droxidopa—Dopamine—DRD5—attention deficit hyperactivity disorder	0.000509	0.0664	CrCbGaD
Droxidopa—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000495	0.0109	CbGeAlD
Droxidopa—ADRB1—brain—attention deficit hyperactivity disorder	0.000479	0.0105	CbGeAlD
Droxidopa—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000477	0.0105	CbGeAlD
Droxidopa—ADRA2C—nervous system—attention deficit hyperactivity disorder	0.000472	0.0103	CbGeAlD
Droxidopa—Epinephrine—ADRA2C—attention deficit hyperactivity disorder	0.000468	0.0611	CrCbGaD
Droxidopa—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000466	0.0102	CbGeAlD
Droxidopa—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000458	0.01	CbGeAlD
Droxidopa—ADRA2C—central nervous system—attention deficit hyperactivity disorder	0.000454	0.00996	CbGeAlD
Droxidopa—ADRA2C—cerebellum—attention deficit hyperactivity disorder	0.000444	0.00973	CbGeAlD
Droxidopa—Methyldopa—ADRA2A—attention deficit hyperactivity disorder	0.000419	0.0547	CrCbGaD
Droxidopa—SLC6A2—brain—attention deficit hyperactivity disorder	0.000407	0.00892	CbGeAlD
Droxidopa—ADRA1A—brain—attention deficit hyperactivity disorder	0.000379	0.0083	CbGeAlD
Droxidopa—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000377	0.00825	CbGeAlD
Droxidopa—Levonordefrin—ADRA2A—attention deficit hyperactivity disorder	0.000371	0.0485	CrCbGaD
Droxidopa—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000362	0.00795	CbGeAlD
Droxidopa—ADRA2C—brain—attention deficit hyperactivity disorder	0.000361	0.00791	CbGeAlD
Droxidopa—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000354	0.00777	CbGeAlD
Droxidopa—Dopamine—COMT—attention deficit hyperactivity disorder	0.000321	0.0419	CrCbGaD
Droxidopa—ADRA2A—brain—attention deficit hyperactivity disorder	0.000288	0.00631	CbGeAlD
Droxidopa—L-DOPA—DRD4—attention deficit hyperactivity disorder	0.00028	0.0365	CrCbGaD
Droxidopa—Dopamine—DRD4—attention deficit hyperactivity disorder	0.00026	0.034	CrCbGaD
Droxidopa—Dopamine—MAOA—attention deficit hyperactivity disorder	0.000242	0.0316	CrCbGaD
Droxidopa—L-DOPA—DRD3—attention deficit hyperactivity disorder	0.000241	0.0315	CrCbGaD
Droxidopa—L-DOPA—DRD1—attention deficit hyperactivity disorder	0.000237	0.0309	CrCbGaD
Droxidopa—Dopamine—DRD3—attention deficit hyperactivity disorder	0.000224	0.0293	CrCbGaD
Droxidopa—Dopamine—DRD1—attention deficit hyperactivity disorder	0.00022	0.0288	CrCbGaD
Droxidopa—Norepinephrine—ADRA2A—attention deficit hyperactivity disorder	0.00022	0.0287	CrCbGaD
Droxidopa—Dopamine—SLC6A3—attention deficit hyperactivity disorder	0.000209	0.0273	CrCbGaD
Droxidopa—Epinephrine—ADRA2A—attention deficit hyperactivity disorder	0.0002	0.0261	CrCbGaD
Droxidopa—Norepinephrine—DRD2—attention deficit hyperactivity disorder	0.000167	0.0218	CrCbGaD
Droxidopa—L-DOPA—DRD2—attention deficit hyperactivity disorder	0.000167	0.0218	CrCbGaD
Droxidopa—Dopamine—SLC6A4—attention deficit hyperactivity disorder	0.000156	0.0204	CrCbGaD
Droxidopa—Dopamine—DRD2—attention deficit hyperactivity disorder	0.000155	0.0203	CrCbGaD
Droxidopa—ADRA2B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.72e-05	0.000159	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.71e-05	0.000159	CbGpPWpGaD
Droxidopa—ADRB2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	2.71e-05	0.000159	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.68e-05	0.000157	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	2.67e-05	0.000157	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.66e-05	0.000156	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.66e-05	0.000156	CbGpPWpGaD
Droxidopa—DDC—Metabolism—COMT—attention deficit hyperactivity disorder	2.64e-05	0.000155	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	2.64e-05	0.000155	CbGpPWpGaD
Droxidopa—ADRB3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.63e-05	0.000154	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.63e-05	0.000154	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	2.63e-05	0.000154	CbGpPWpGaD
Droxidopa—DDC—Metabolism—MAOA—attention deficit hyperactivity disorder	2.62e-05	0.000154	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.61e-05	0.000153	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	2.59e-05	0.000152	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	2.56e-05	0.00015	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.55e-05	0.000149	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.54e-05	0.000149	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	2.54e-05	0.000149	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.54e-05	0.000149	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.53e-05	0.000148	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	2.52e-05	0.000148	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.5e-05	0.000146	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.49e-05	0.000146	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.49e-05	0.000146	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.48e-05	0.000145	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.48e-05	0.000145	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.47e-05	0.000145	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.47e-05	0.000145	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.46e-05	0.000144	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.46e-05	0.000144	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.45e-05	0.000144	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.45e-05	0.000143	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.44e-05	0.000143	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.43e-05	0.000142	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.43e-05	0.000142	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.42e-05	0.000142	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.42e-05	0.000142	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.41e-05	0.000142	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.41e-05	0.000141	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.4e-05	0.000141	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.4e-05	0.000141	CbGpPWpGaD
Droxidopa—ADRB3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.39e-05	0.00014	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.39e-05	0.00014	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.38e-05	0.00014	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.37e-05	0.000139	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.37e-05	0.000139	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.37e-05	0.000139	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.36e-05	0.000138	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.36e-05	0.000138	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	2.36e-05	0.000138	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.34e-05	0.000137	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	2.33e-05	0.000137	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.33e-05	0.000137	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.32e-05	0.000136	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.31e-05	0.000136	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	2.3e-05	0.000135	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.3e-05	0.000135	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.3e-05	0.000135	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.29e-05	0.000134	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.28e-05	0.000134	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.27e-05	0.000133	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.26e-05	0.000133	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.26e-05	0.000132	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.25e-05	0.000132	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.25e-05	0.000132	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.25e-05	0.000132	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.24e-05	0.000131	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	2.24e-05	0.000131	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.23e-05	0.000131	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.23e-05	0.000131	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	2.23e-05	0.000131	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.22e-05	0.00013	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.22e-05	0.00013	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.22e-05	0.00013	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.22e-05	0.00013	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.21e-05	0.00013	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.21e-05	0.00013	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.21e-05	0.00013	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.2e-05	0.000129	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.2e-05	0.000129	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.19e-05	0.000129	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.19e-05	0.000129	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.18e-05	0.000128	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.18e-05	0.000128	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.18e-05	0.000128	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.18e-05	0.000128	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.17e-05	0.000127	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	2.17e-05	0.000127	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.17e-05	0.000127	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.16e-05	0.000126	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.16e-05	0.000126	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.14e-05	0.000126	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	2.14e-05	0.000126	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.13e-05	0.000125	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.11e-05	0.000124	CbGpPWpGaD
Droxidopa—PAH—Disease—EP300—attention deficit hyperactivity disorder	2.09e-05	0.000123	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	2.08e-05	0.000122	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.07e-05	0.000122	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.07e-05	0.000121	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.06e-05	0.000121	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	2.06e-05	0.000121	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.04e-05	0.00012	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.04e-05	0.00012	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.03e-05	0.000119	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.03e-05	0.000119	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.02e-05	0.000118	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.01e-05	0.000118	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.01e-05	0.000118	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.01e-05	0.000118	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.01e-05	0.000118	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2e-05	0.000118	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2e-05	0.000117	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.98e-05	0.000116	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.98e-05	0.000116	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.96e-05	0.000115	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	1.96e-05	0.000115	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.94e-05	0.000114	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.93e-05	0.000113	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	1.92e-05	0.000112	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—TPH2—attention deficit hyperactivity disorder	1.89e-05	0.000111	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.89e-05	0.000111	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.88e-05	0.00011	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.87e-05	0.00011	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	1.87e-05	0.00011	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	1.86e-05	0.000109	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—DPYD—attention deficit hyperactivity disorder	1.86e-05	0.000109	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	1.86e-05	0.000109	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.85e-05	0.000108	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.85e-05	0.000108	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	1.82e-05	0.000107	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.81e-05	0.000106	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.81e-05	0.000106	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	1.8e-05	0.000106	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	1.79e-05	0.000105	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	1.78e-05	0.000105	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.76e-05	0.000103	CbGpPWpGaD
Droxidopa—PAH—Metabolism—EP300—attention deficit hyperactivity disorder	1.75e-05	0.000103	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	1.74e-05	0.000102	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.73e-05	0.000102	CbGpPWpGaD
Droxidopa—ADRA1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.72e-05	0.000101	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	1.69e-05	9.88e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.68e-05	9.87e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	1.68e-05	9.84e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.67e-05	9.78e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.65e-05	9.65e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.64e-05	9.62e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	1.64e-05	9.59e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.61e-05	9.47e-05	CbGpPWpGaD
Droxidopa—ADRB1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.56e-05	9.17e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.56e-05	9.14e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.56e-05	9.13e-05	CbGpPWpGaD
Droxidopa—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.55e-05	9.08e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	1.54e-05	9.02e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	1.54e-05	9.02e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.53e-05	8.99e-05	CbGpPWpGaD
Droxidopa—ADRB2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.53e-05	8.97e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	1.52e-05	8.94e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.51e-05	8.87e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	1.51e-05	8.87e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.5e-05	8.8e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.47e-05	8.62e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.46e-05	8.55e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.45e-05	8.52e-05	CbGpPWpGaD
Droxidopa—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.45e-05	8.49e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.44e-05	8.45e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.44e-05	8.44e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.43e-05	8.38e-05	CbGpPWpGaD
Droxidopa—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.42e-05	8.35e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.42e-05	8.33e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.41e-05	8.29e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.41e-05	8.27e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.41e-05	8.25e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	1.41e-05	8.25e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.39e-05	8.14e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.37e-05	8.02e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.36e-05	7.98e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.36e-05	7.98e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.35e-05	7.94e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.34e-05	7.86e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.34e-05	7.84e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.32e-05	7.77e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.31e-05	7.71e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.31e-05	7.71e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.31e-05	7.69e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.3e-05	7.63e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	1.3e-05	7.62e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.3e-05	7.6e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.29e-05	7.58e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.29e-05	7.56e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.29e-05	7.54e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.27e-05	7.47e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.27e-05	7.47e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.27e-05	7.42e-05	CbGpPWpGaD
Droxidopa—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.27e-05	7.42e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.26e-05	7.42e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.26e-05	7.37e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.25e-05	7.3e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.23e-05	7.21e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.23e-05	7.19e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	1.21e-05	7.11e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.21e-05	7.07e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.2e-05	7.06e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.2e-05	7.02e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.19e-05	6.98e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.19e-05	6.98e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.19e-05	6.96e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.19e-05	6.95e-05	CbGpPWpGaD
Droxidopa—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.18e-05	6.89e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.17e-05	6.87e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.17e-05	6.87e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.15e-05	6.74e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	1.15e-05	6.73e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	1.14e-05	6.68e-05	CbGpPWpGaD
Droxidopa—DDC—Metabolism—EP300—attention deficit hyperactivity disorder	1.13e-05	6.64e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.11e-05	6.5e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.11e-05	6.49e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.11e-05	6.48e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.09e-05	6.4e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.07e-05	6.28e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.07e-05	6.26e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.05e-05	6.18e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.04e-05	6.1e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.03e-05	6.03e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.96e-06	5.84e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	9.85e-06	5.78e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9.69e-06	5.68e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.66e-06	5.67e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	9.32e-06	5.46e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	9.25e-06	5.42e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.21e-06	5.4e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9e-06	5.28e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.39e-06	4.92e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.31e-06	4.87e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.2e-06	4.81e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.76e-06	4.55e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.64e-06	4.48e-05	CbGpPWpGaD
Droxidopa—ADRB3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.49e-06	4.39e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.79e-06	3.98e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.31e-06	3.7e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	4.92e-06	2.88e-05	CbGpPWpGaD
Droxidopa—ADRA1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.88e-06	2.86e-05	CbGpPWpGaD
Droxidopa—ADRB1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.44e-06	2.61e-05	CbGpPWpGaD
Droxidopa—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.4e-06	2.58e-05	CbGpPWpGaD
Droxidopa—ADRB2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.35e-06	2.55e-05	CbGpPWpGaD
Droxidopa—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.11e-06	2.41e-05	CbGpPWpGaD
Droxidopa—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.05e-06	2.37e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	4e-06	2.34e-05	CbGpPWpGaD
Droxidopa—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.6e-06	2.11e-05	CbGpPWpGaD
Droxidopa—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.34e-06	1.96e-05	CbGpPWpGaD
